Drug-coated Balloon Catheter Market

Drug-coated Balloon Catheter Market Forecast and Outlook (2026 to 2036)

• In 2025, the drug-coated balloon catheter market was valued at USD 4.7 billion.
• Based on Fact.MR estimates, demand is estimated to grow to USD 5.1 billion in 2026 and USD 10.9 billion by 2036. Fact.MR projects a CAGR of 7.9% during the forecast period.

Summary of Drug-coated Balloon Catheter Market

• Market Definition
  • The market includes drug-coated angioplasty balloons used to treat vascular lesions while delivering an antiproliferative drug locally.
• Demand Drivers
  • Coronary ISR treatment gained commercial importance in the U.S. after FDA approval of AGENT in 2024.
  • Peripheral DCBs continue to serve femoropopliteal and AV access applications across multiple vendor portfolios.
  • Updated FDA review does not indicate a late mortality signal for paclitaxel-coated peripheral devices, improving category confidence.
• Key Segments Analyzed
  • By Product Type: Peripheral Drug-coated Balloons are estimated to lead with approximately 44% share in 2026, supported by broad femoropopliteal and AV access use.
  • By Drug Type: Paclitaxel-coated Balloons are expected to hold approximately 71% share in 2026, driven by current commercial product availability.
  • By Application: In-Stent Restenosis is projected to account for approximately 26% share in 2026, supported by coronary DCB expansion and peripheral ISR use.
  • By End Use: Hospitals are expected to contribute approximately 49% share in 2026, backed by concentration of vascular intervention procedures.
  • By Geography: India leads growth at 8.8% CAGR through 2036, supported by broader intervention access.
• Analyst Opinion at FACT.MR
  • Shambhu Nath Jha, Senior Analyst at Fact.MR, opines, “this market as a lesion-management and restenosis-control category rather than a niche balloon-device segment. Buyers are not only paying for angioplasty. They are paying for local drug delivery, no permanent implant, and broader treatment flexibility across selected lesion types.”
• Strategic Implications
  • Invest in DCB platforms that pair consistent drug transfer with strong lesion-crossing and deliverability characteristics.
  • Build technical sales capability around lesion selection, vessel preparation, and vascular-bed-specific evidence rather than coating alone.
  • Position coronary and peripheral DCBs where operators want restenosis control without permanent scaffolding.

The market is projected to generate USD 5.8 billion in absolute opportunity between 2026 and 2036. Growth is being supported by continued use in coronary ISR, broad peripheral artery disease treatment, and expanding acceptance of drug delivery without a permanent scaffold in selected lesions. FDA states that AGENT received approval on February 29, 2024 for coronary ISR, which materially expanded the U.S. coronary DCB category. SCAI also noted in 2024 that drug-coated balloon angioplasty had recently received FDA approval as a treatment strategy for ISR. [1]

India is projected to lead with a CAGR of 8.8% through 2036, driven by expanding PCI and peripheral intervention capacity. China follows at 8.4%, supported by higher revascularization volumes and broader vascular care access. The United States is expected to grow at 7.6%, underpinned by coronary ISR uptake after AGENT approval and established PAD intervention volumes. Germany records 7.1%, backed by structured coronary and peripheral revascularization practice. Brazil grows at 6.8%, supported by widening vascular intervention access.

Segmental Analysis

Drug-coated Balloon Catheter Market Analysis by Product Type

Peripheral drug-coated balloons continue to lead due to their strong clinical relevance in femoropopliteal disease and the presence of multiple established commercial platforms in peripheral intervention. Their use is supported by broad applicability in superficial femoral and popliteal artery treatments. Peripheral drug-coated balloons are estimated to hold 44% share in 2026. Philips positions Stellarex for use in superficial femoral and popliteal arteries, while Medtronic highlights IN. PACT Admiral and IN. PACT 018 as clinically proven primary endovascular therapies for femoropopliteal disease. [4]

• Peripheral DCBs lead because they fit the broadest currently commercialized lesion set.
• Coronary DCBs remain attractive where ISR treatment without another stent is preferred.
• AV Access DCBs gain relevance where fistula restenosis management needs longer patency support than PTA alone.

Drug-coated Balloon Catheter Market Analysis by Drug Type

Paclitaxel-coated balloons are expected to hold approximately 71% share in 2026, as most currently marketed coronary and peripheral drug-coated balloon platforms are based on paclitaxel, reflecting established clinical use and product availability. Boston Scientific positions its AGENT DCB platform in coronary applications, while Philips (Stellarex) and Medtronic (IN.PACT series) reinforce the dominance of paclitaxel-based technologies across peripheral interventions.

• Paclitaxel-coated balloons lead because they dominate current commercial DCB portfolios in official product sources.
• Sirolimus-coated balloons remain attractive where newer coronary use cases and future product differentiation are being explored.
• Other drug approaches gain relevance where lesion-specific clinical strategies continue to evolve.

Drug-coated Balloon Catheter Market Analysis by Application

In-Stent Restenosis is projected to account for approximately 26% share in 2026. This segment leads because coronary ISR is now a clearly defined DCB use case in the U.S. and remains central to category identity. FDA states that AGENT is intended for adult PCI patients in coronary arteries 2.0 mm to 4.0 mm in diameter and lesions up to 26 mm in length for ISR treatment. [5]

• ISR leads because it is the clearest current coronary DCB indication.
• Femoropopliteal disease remains important where peripheral DCBs are already broadly established.
• Arteriovenous access dysfunction gains relevance where DCBs are positioned against repeat PTA for fistula stenosis.

Drug-coated Balloon Catheter Market Analysis by End Use

Hospitals are expected to contribute approximately 49% share in 2026. This segment leads because coronary, peripheral, and AV access DCB procedures remain concentrated in hospital-based cath labs and vascular intervention units. FDA’s AGENT documentation states intended users include interventional cardiologists, cath lab technicians, and nurses trained in angiography and PCI.

• Hospitals lead because they anchor most coronary and peripheral endovascular interventions.
• Cardiac catheterization laboratories remain attractive where coronary ISR treatment is concentrated.
• Specialty vascular centers gain traction where peripheral and AV access procedures are growing.

Drivers, Restraints, and Opportunities

The market is being shaped by the need to reduce restenosis while preserving procedural flexibility in selected lesions. Structural demand is anchored in the absence of a permanent scaffold, especially in ISR and selected peripheral lesions. SCAI notes that compared with DES, DCBs are associated with faster vessel healing and reduced thrombotic burden because there is no metallic scaffold or polymer left inside the coronary artery.

The main restraint is indication specificity and category maturity differences across vascular beds. Coronary DCB use in the U.S. remains centered on ISR rather than broad de novo coronary use, and lesion preparation remains critical to success. Peripheral DCBs also remain tied to vascular-bed-specific evidence and operator confidence. This means suppliers must prove not only coating performance but also procedural practicality and lesion-specific value.

• Coronary ISR remains the clearest opportunity where operators want restenosis treatment without another stent layer.
• Peripheral DCBs create stronger value where durable patency and repeat-intervention reduction are prioritized.
• AV access DCBs offer higher-value opportunity where fistula patency and repeat procedure burden remain major concerns.

Regional Analysis

The market is assessed across North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, covering 40+ countries with demand profiles shaped by PCI access, PAD treatment volume, hospital infrastructure, and endovascular device availability. The country growth rates below are model-based estimates.

North America Drug-coated Balloon Catheter Market Analysis

North America remains an important commercial region because it combines expanding coronary DCB availability, mature PAD intervention activity, and strong hospital-based endovascular capacity. The region has seen meaningful clinical and regulatory developments that are reshaping coronary and peripheral DCB adoption.

• United States: Expansion in coronary ISR treatment options and established PAD intervention volumes support growth. The market is projected to expand at approximately 7.6% CAGR through 2036, driven by increasing use of drug-coated balloons in both coronary and peripheral procedures. Adoption is supported by improving physician familiarity, broader product availability, and continued interest in leaving nothing behind strategies.

Europe Drug-coated Balloon Catheter Market Analysis

Europe remains a technically structured region where adoption is closely tied to established revascularization practices, broader clinical familiarity with DCBs, and ongoing evaluation of treatment strategies across lesion types.

• Germany: Germany plays a central role in Europe’s interventional cardiology landscape due to high procedure volumes and strong clinical expertise. The market is projected to grow at around 7.1% CAGR by 2036, supported by continued use of DCBs in coronary and peripheral applications. Adoption is driven by clinician experience, guideline-informed practice, and interest in alternative strategies to stent-based treatment in selected cases.

Asia Pacific and Latin America Drug-coated Balloon Catheter Market Analysis

Asia Pacific offers the strongest long-term expansion potential because it combines increasing coronary and peripheral intervention capacity, improving healthcare infrastructure, and rising access to endovascular treatments. Adoption is accelerating as clinicians expand beyond conventional angioplasty toward drug-delivery-based approaches.

• India: Expanding PCI and peripheral intervention capacity support demand. The market is projected to grow at close to 8.8% CAGR from 2026 to 2036, driven by increasing hospital infrastructure, rising cardiovascular disease burden, and broader access to advanced endovascular therapies.
• China: High revascularization volumes and expanding healthcare capacity support growth. The market is expected to expand at approximately 8.4% CAGR through 2036, with increasing use of DCBs across coronary and peripheral procedures.
• Brazil: Rising access to vascular interventions and improving hospital capabilities support steady growth. The market is projected to grow at around 6.8% CAGR over the forecast period, driven by broader adoption of endovascular therapies and increasing clinical familiarity with drug-coated balloon technology.

Competitive Aligners for Market Players

The market is moderately concentrated at the coronary and peripheral endovascular device platform level, while broader deployment remains hospital- and operator-controlled. Competitive strength comes from the ability to combine drug-transfer efficiency, deliverability, lesion preparation compatibility, and vascular-bed-specific evidence. Suppliers need more than a coated balloon claim. They need a clear explanation of how the platform improves procedural flexibility and restenosis control in real-world lesions.

Competitive advantage is defined by coating technology, drug dose strategy, lesion-crossing profile, and fit with coronary, peripheral, or AV access workflows.

Key Players

• Boston Scientific
• Philips
• Medtronic
• Becton Dickinson
• BIOTRONIK

Bibliography

• [1] SCAI. Coronary ISR commentary stating that DCB angioplasty had recently received FDA approval as a treatment strategy for in-stent restenosis.
• [2] ESC. 2024 communication on DCB versus DES in non-complex coronary artery disease.
• [3] FDA. AGENT PMA approval summary and instructions-for-use materials covering intended users and lesion parameters.
• [4] Medtronic. IN.PACT Admiral and IN.PACT 018 product materials describing primary endovascular therapy use in femoropopliteal disease.
• [5] FDA. AGENT Paclitaxel-Coated Balloon Catheter approval materials for coronary ISR, including PMA and approval summary pages.

This Report Addresses

• Strategic intelligence on drug-coated balloon catheter demand across coronary ISR, peripheral artery disease, AV access dysfunction, and lesion-specific vascular intervention.
• Market forecast from USD 5.1 billion in 2026 to USD 10.9 billion by 2036 at a CAGR of 7.9%.
• Growth opportunity mapping across coronary DCBs, femoropopliteal DCBs, AV access DCBs, and paclitaxel- and sirolimus-based coated balloon platforms.
• Segment analysis by product type, drug type, application, end use, and region.
• Regional outlook covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
• Competitive analysis of major participants serving coronary and peripheral DCB, endovascular lesion management, and vascular intervention device ecosystems.
• Restenosis-control and scaffold-free intervention analysis covering vessel preparation, drug transfer, lesion-specific use, and procedural flexibility.
• Market interpretation built around coronary ISR expansion, peripheral intervention demand, and ongoing preference for local drug delivery without permanent implants.

Drug-coated Balloon Catheter Market Definition

The market covers angioplasty balloon catheters coated with antiproliferative drugs used to treat vascular lesions while reducing restenosis risk after vessel preparation and balloon inflation. It includes coronary and peripheral DCBs, AV access DCBs, and related lesion-specific balloon platforms.

Drug-coated Balloon Catheter Market Inclusions

Covers global and regional forecasts from 2026 to 2036. Includes coronary DCBs for ISR, femoropopliteal DCBs, AV access DCBs, and other drug-coated angioplasty balloons used after lesion preparation in adult vascular intervention settings.

Drug-coated Balloon Catheter Market Exclusions

Excludes drug-eluting stents, plain balloon angioplasty catheters without drug coating, atherectomy systems, and peripheral scaffolds unless a drug-coated balloon remains the core product role. It also excludes drug-coated balloons used outside vascular intervention workflows.

Drug-coated Balloon Catheter Market Research Methodology

• Primary Research:Interviews with interventional cardiologists, vascular specialists, cath lab managers, hospital procurement teams, and endovascular device distributors.
• Desk Research:Uses current official materials from FDA, SCAI, Boston Scientific, Philips, and Medtronic tied to indications, product positioning, and vascular intervention use. [2]
• Market-Sizing and Forecasting:Hybrid model using coronary ISR demand, peripheral angioplasty volumes, AV access intervention demand, product approvals, and lesion-specific DCB adoption trends.
• Data Validation and Update Cycle:Validated using official product pages, FDA approval and safety materials, and recurring checks on coronary and peripheral DCB positioning. [3]